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INTRODUCTION 
 
 
In recent decades, the usage and implementation 
of high-sugar content food products have 
accelerated the presence of metabolic syndromes 
like obesity and diabetes (Low et al., 2016). If 
current trends in diet and lifestyle continue to 
accelerate, an estimated 38% of the world’s 
 
ABSTRACT  Rising rates of obesity and type 2 diabetes have prompted the usage and recommendation 
of nonnutritive sweeteners (NNS) as harmless sugar substitutes in attempts to decrease caloric intake. 
Contrary to the common belief that NNS remain physiologically inert post-consumption, evidence 
highlights their ability to alter metabolic processes via interactions in the gastrointestinal tract. An 
extensive review was conducted on the potential NNS-induced metabolic deviances by way of two non-
mutually exclusive mechanisms. One possible mechanism involves their ability (or inability) to induce 
the secretion of GLP-1, a hormone produced in the gut that promotes satiety and accelerates glucose-
dependent insulin secretion by interacting with sweet-taste receptors in the small intestine. Though NNS 
(sucralose, Ace K, and Rebaudioside A) show a high rate of GLP-1 secretion during in vitro studies, 
there are many discrepancies in results from human in vivo studies. A second mechanism proposes that 
NNS alter the composition of the gut microbiota, a vast community of microorganisms responsible for 
digesting food, releasing metabolites, and synthesizing vitamins. Differing forms of dysbiosis, 
alterations in bacterial composition, are observed, including an increased ratio of Firmicutes to 
Bacteroidetes and an increase in Lactobacilli spp. in exclusive studies, upon NNS exposure. Few 
experiments assessing NNS impact on the gut microbiota have been conducted with human subjects. 
Further investigations, specific to human subjects, should be explored in order to assess the true extent 
to which NNS impact incretin secretion and alterations in the gut microbiota.  
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 population will be overweight and another 20% 
will be obese by the year 2030 (Smith et al., 
2016). Abnormally high consumption rates of 
energy-dense foods with large contents of sugars 
and saturated fats not only serve as a leading 
cause for obesity but also contribute largely to 
type 2 diabetes, hypertension, and cardiovascular 
disease (Laffitte et al., 2014). In attempt to 
diminish the overbearing and unhealthful trends 
in diet, substitutes for sugars, nonnutritive 
sweeteners (NNS), have been developed. NNS 
can deliver a high potency content of sweetness 
in a miniscule concentration with negligent 
caloric intake by binding with strong affinity to 
one or more sites on the sweet taste receptor in 
the oral cavity (Burke et al., 2015). Until recent 
consideration, NNS were recommended for 
people who were approaching obesity and/or 
onset diabetes to aid in health improvement by 
providing a sweet taste without affecting caloric 
intake and glycemic responses; however, on 
accounts of multiple studies, NNS consumption 
over a prolonged period of time may promote 
glucose intolerance, obesity and its associative 
commodities (Nettleton et al., 2016). Currently, 
the FDA has recognized six NNS for use in the 
United States: acesulfame potassium, aspartame, 
neotame, saccharin, sucralose, and Rebaudioside 
A. The presence of these sweeteners has 
dominated many components of our diet and 
personal care products including “diet” or “zero-
calorie” drinks, chewing gum, toothpaste, and 
many other foods and drinks for enhancement of 
flavor (Sylvetsky et al., 2017). The discovery of 
sweet taste receptors in the gut has prompted the 
possibility for NNS to interact with them in a 
similar fashion to which they bind to the taste 
receptors in the oral cavity (Laffitte et al., 2014; 
Margolskee et al., 2007; Pepino et al., 2011). 
 
Contrary to the common belief that NNS are 
physiologically inert compounds, there is 
overwhelming evidence that highlights their 
ability to alter metabolic processes that control 
homeostasis post-consumption via interactions in 
the gastrointestinal tract. This review focuses on 
the impact of NNS on the secretion of satiety 
hormone glucagon-like peptide-1 (GLP-1) and 
NNS-induced alterations in the gut microbiota. In 
terms of evolution, the highly innate sensation 
and perception of taste has provided vertebrates 
with an expansive pallet capable of detecting 
beneficial and toxic nutrients, thus enabling them 
to successfully navigate their surroundings. Most 
notably, the innate preference to sweet taste 
evolved to detect the presence of valuable 
carbohydrates, and the interactions between 
sweeteners and sweet taste receptors (in the oral 
and extra oral cavities) predict caloric content and 
evoke physiological responses that prepare the 
gastrointestinal tract for digestion according to 
the intensity and quantity (Pepino et al., 2011). 
The gastrointestinal tract is home to an elaborate 
network of enteroendocrine cells that release 
hormones to signal digestive, homeostatic, and 
behavioral responses by responding to the enteric 
nervous system and effectively communicating to 
target organs. One of these processes involves the 
secretion of a satiety hormone, GLP-1 which 
serves a vital function by amplifying glucose-
dependent insulin secretion (Baggio et al., 2007; 
Jang et al., 2007; Takai et al., 2015).  
 
A large part of the human metabolism is 
dependent on the gut microbiota for processing 
food that would otherwise be indigestible and 
synthesizing valuable vitamins, such as vitamin 
B12 (D’Argenio et al., 2015). Additionally, the 
gut microbiota has been identified as a key player 
in the intricate mechanisms of nutrient 
metabolism in the gut and in the neuronal 
communication and regulation of the 
hypothalamic-pituitary-adrenal axis (Sudo, 
2014). Though the recently proposed 
mechanisms of such interactions are not 
definitive, their presence and predicted impact 
makes the microbiome a likely contributor to 
metabolic syndrome. Metabolic syndrome is 
characterized by a combination of three or more 
of the following symptoms: abdominal obesity, 
high triglycerides, low high-density lipoprotein-
cholesterol (HDL-C) and heightened blood 
pressure and blood sugar (Sudo, 2014). Those 
affected by metabolic syndrome are subject to a 
significant increase risk to cardiovascular 
disease, diabetes mellitus, non-alcoholic fatty 
liver disease, polycystic ovarian syndrome, 
dementia, and cancer.  A predicted contributor 
and common characteristic of metabolic 
syndrome is chronic inflammation which can be 
attributed by various environmental and genetic 
factors (Melvin et al., 2016). One such 
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 environmental factor includes alterations in the 
gut microbiota. Changes in gut bacterial 
composition have been linked to inflammatory 
side-effects that promote insulin resistance, fat 
storage and weight gain in the host which makes 
it a potential contributor to the development of 
metabolic syndrome, obesity and/or type 2 
diabetes (Daly et al., 2014; Palmnäs et al., 2014). 
  
Being that both metabolic components, gut 
hormone secretion and the gut microbiota, are 
localized in the gastrointestinal mucosa and 
enteric nervous system, they are likely to have 
intersecting impacts when affected by NNS. 
Specifically, recent studies have indicated that 
the gut bacterial composition can affect the 
development and regulation of the hypothalamic-
pituitary-adrenal axis and behavior via 
mechanisms of gut hormone secretion (Sudo, 
2014). Additionally, host-derived satiety 
hormones were found to increase local bacterial 
proliferative capacity as well as pathogenicity 
(Sudo, 2014). The interactive communication 
between the microbiome and enteroendocrine 
cell hormone secretion reveals their non-mutually 
exclusive relationship and has further 
implications when assessing their response to 
NNS. Though the mechanistic connection 
between the two are not solidified, both aspects 
serve as important targets individually when 
assessing the metabolic impacts of NNS. In 
exploring the impact of NNS on satiety hormone 
secretion and the gut microbiota, several 
mechanisms will be proposed that enable these 
discrepancies and serve as prospective points of 
interest for future research on metabolic health. 
The directionality of this review is provided by a 
study outline (see Figure 1).  
 
METHODS 
 
PubMed database searches were carried out using 
keywords and phrases relevant to this review: 
non-nutritive sweeteners, gut hormones, GLP-1, 
GIP, gut microbiota, body-weight, insulin, 
homeostasis, and glucagon. Searches were 
filtered by “Best Match,” and their publishing 
dates were considered in order to include the most 
current information. 
  
RESULTS  
POTENTIAL MECHANISMS FOR NNS-
INDUCED METABOLIC DEVIANCES 
 
1.a. Gut Function: The Enteroendocrine System 
 
The gastrointestinal tract consists of a series of 
hollow organs that enable the breakdown, 
metabolism, and distribution of nutrients ingested 
from the environment. Specific to the gut, the 
enteric nervous and enteroendocrine systems 
work together to initiate digestion and effectively 
communicate proper metabolic signals (via gut-
derived peptides) to the brain to commence 
Figure 1. Study Overview. Outlined above, the direction of the review began with a general concern for NNS 
and their impact on metabolic process then succinctly moved toward their impact on satiety hormone secretion 
and the gut microbiota. Studies marked with “*” were conducted in vitro. 
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 chemical and behavioral responses. Sensory 
neurons in the gastrointestinal tract partake in 
homeostasis, danger detection, and protective 
responses by communicating with surrounding 
intestinal cells (Melvin et al., 2016). The 
gastrointestinal tract produces a vast amount of 
peptide hormones that initiate specific responses. 
Specialized cells in the gastrointestinal tract, 
enteroendocrine cells, are responsible for the 
endocrine action of the gut (Melvin et al., 2016).  
During periods of fasting, ghrelin is released by 
specific enteroendocrine cells found in the gastric 
fondus. In contrast, leptin, produced by adipose 
cells, inhibits hunger and regulates long-term 
energy storage (Melvin et al., 2016). 
Additionally, a high presence of lipid initiates 
peptide YY (PYY) secretion in enteroendocreine 
cells in the ileum and results in a reduction in 
caloric intake (30%) (Melven et al., 2016). Also 
termed as “incretins,” gut hormones, GLP-1 and 
gastric inhibitory polypeptide (GIP), are directly 
involved in the transmission of sweet-taste 
signals from carbohydrates by accelerating 
glucose-dependent insulin secretion in pancreatic 
ß-cells (Henquinn et al., 2012; van der Wielen et 
al., 2016). GLP-1, the more influential of the two, 
is secreted by intestinal L cells located in the 
gastrointestinal mucosa and acts locally within 
the intestinal wall to initiate enteroenteric 
reflexes which slow the rate of gastric emptying 
(Nadkarni et al., 2014). Additionally, GLP-1 
regulates glucose homeostasis by inhibiting the 
release of glucagon, therefore decreasing the 
breakdown of glycogen and lowering blood 
glucose levels (van der Wielen et al., 2016). For 
these reasons, GLP-1 has been actively 
researched as a possible target for the treatment 
and prevention of obesity and type 2 diabetes. 
The relationship and communication between 
intestinal L cells and pancreatic -cells via 
incretins to secrete insulin has been dubbed the 
incretin effect. It was discovered that oral glucose 
administration promoted substantially greater 
amounts of insulin secretion compared to an 
intravenous injection of glucose, indicating the 
role of incretins in amplifying insulin secretion 
(Delgado-Aros et al., 2002; Swithers et al., 2013). 
Incretins are estimated to account for 50-70% of 
the total insulin production post-meal 
consumption (Steinert et al., 2011). Considering 
the direct correlation with enhanced insulin 
secretion, inhibition of glucagon release, and 
promoted feelings of satiety, GLP-1 is a vital 
messenger examined.  
 
1.b. The T1R2/T1R3 Taste Receptor Expressed 
In Extraoral Tissues 
 
NNS have the unique ability to elicit a sweet-taste 
response that ranges between 100-800 times 
sweeter than an equivalent amount of glucose, 
thus allowing their implementation for food/drink 
product to be miniscule. Due to their unique 
chemical structure, the predicted mechanism for 
the heightened response is an increase in bonding 
affinity for the sweet taste receptor. Sweet taste 
perception is initiated in the oral cavity by the 
binding of a sweet-tasting molecule to a sweet 
taste receptor, a G-protein coupled receptor with 
two 7-transmembrane subunits, taste receptor 
type 1 member 2 and taste receptor type 1 
member 3 (T1R2/T1R3) (Burke et al., 2015). The 
heterodimeric receptor provides input on the 
caloric contents of ingested food by initializing 
cellular and neural responses when in contact 
with natural sugars or non-nutritive sweeteners 
(Laffitte et al., 2014). Within the last 5 years, the 
T1R2/T1R3 sweet taste receptor and its 
associated taste signal transduction molecules 
have been discovered in tissues beyond the 
mouth, including the gastrointestinal tract, 
pancreas, adipose tissues, and brain (Kyriazis et 
al., 2012; Laffitte et al., 2014; Nakagawa et al., 
2009; Oya et al., 2011; Takai et al., 2015). The 
presence of such receptors in tissues beyond the 
oral cavity suggests an additional physiological 
purpose than simply sweet-taste detection; 
Specific to the intestinal tract, the T1R2/T1R3 
receptors, integrated within the membrane of 
enteroendocrine cells, trigger physiological 
responses that facilitate metabolic processes and 
stimulate glucose absorption (Margolskee et al., 
2007; Sclafani et al., 2007; Shirazi-Beechey et 
al., 2011). Glucose absorption in the gut is 
essential for the host as nutrients from food must 
be transferred from the gut into the bloodstream 
for delivery to target organs. Significant evidence 
supports that glucose uptake via sodium-
dependent glucose transporter isoform 1 
(SGLT1) in enteroendocrine cells is regulated, to 
a degree, by the activation of the T1R2/T1R3 
receptors and their related components of G-
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 protein-linked signaling pathways (i.e. -
gutducin, phospholipase C  type 2, and transient 
receptor potential channel M5 [TRPM5]) (Jang et 
al., 2007; Margolskee et al., 2007; Merigo et al., 
2011; Rozengurt et al., 2006). Margolskee et al., 
and others have demonstrated that knockout mice 
lacking T1R3 or -gustducin were not able to 
increase SGLT1 mRNA and protein expression, 
whereas mice with the components significantly 
elevated expression of SGLT1 upon consumption 
of sugars or artificial sweeteners, indicating that 
the heterodimeric sweet taste receptor had an 
influence on glucose uptake in mice. 
 
The main function of enteroendocrine cells is to 
produce and secrete gastrointestinal hormones, 
incretins, which act as local messengers and aid 
in digestive processes (Baggio et al., 2007). The 
two incretins, GLP-1 and gastric inhibitory 
polypeptide (GIP), also relay information to 
sensory neurons in close proximity via enhancing 
secretion neurotransmitters (Nadkarni et al., 
2014). Incretins, hormones that facilitate the 
rapid digestion of ingested nutrients, are released 
within minutes of meal consumption by 
enteroendocrine cells in the small and large 
intestine (Baggio et al., 2007; Delgado-Aros et 
al., 2002; Nadkarni et al., 2014). Similar to 
glucose uptake via SGLT1, GLP-1 secretion is 
initiated, at least partially, by the activation of the 
T1R2/T1R3 receptors in the small intestine 
(Takai et al., 2015). 
  
1.c. The Initiation of T1R2/T1R3 Receptor, 
GLP-1 Secretion, and Glucose-Dependent 
Insulin Release 
 
There is functional evidence linking the 
T1R2/T1R3 taste receptor and the release of 
incretins in enteroendocrine cells; however, a 
definite mechanism has not been developed. 
Having discovered the same components 
involved in the perception of taste in type II taste 
cells in the tongue, one proposed mechanism 
mirrors this same pathway. As seen in Figure 2, 
the secretion of incretins (GLP-1 & GIP) is 
stimulated by the signal transduction pathway 
initiated at the T1R2/T1R3 receptor. In type II 
taste cells in the oral cavity, stimulation of the 
T1R2/T1R3 receptor causes the dissociation of 
the heterotrimeric guanine-nucleotide-binding G 
protein and its,, and  subunits (-gustducin, 
G3, and G13). This dissociation leads to an 
increase in phospholipase C-2 (PLC-2) activity 
which causes the inositol 1,4,5-triphosphate (IP3) 
receptor to release Ca2+ from intracellular stores 
and the opening of transient potential ion channel, 
transient receptor potential cation channel 
subfamily M member 5 (TRPM5). As a result, the 
membrane is depolarized, and an action potential 
is generated, causing a release of adenosine 
triphosphate (ATP) which acts as a transmitter for 
further gustatory afferents. 
 
Though the mechanism has not been directly 
proven, eneteroendocrine cells are thought to 
follow a similar pathway involving the 
T1R2/T1R3 receptor and the heterotrimeric G 
protein (-gustducin, G3, and G13) and the 
resulting depolarization of the cell membrane 
(Behrens et al., 2011; Gheni et al., 2014; Wu et 
al., 2013). Instead of continuing the transmission 
of gustatory sensory information from the tongue 
to the brain, the action potential generated in the 
enteroendocrine cells facilitates the release of 
hormone-containing vesicles. Further, GLP-1 and 
GIP, are able to effectively aid in post-digestive 
responses. In a study conducted by Jang et al. 
(2007), -gustducin or T1R3 knockout mice did 
not show an increased secretion of GLP-1 to 
direct glucose ingestion.  Additionally, GLP-1 
secretion in L cells was significantly lower in 
mice exposed to a T1R2/T1R3 receptor inhibitor, 
lactisole. Together, their results indicate that taste 
receptor components in enteroendocrine cells are 
directly involved in the secretion of GLP-1 in 
mice. 
 
The two dominant signals that drive insulin 
secretion in pancreatic  cells are generated ATP 
via glucose metabolism and the influx of Ca2+ 
ions. ATP generated by glucose metabolism 
closes the ATP sensitive K+(KATP) channels, 
depolarizing the cell membrane. Voltage-
dependent Ca2+ channels open, allowing the 
influx of Ca2+ and exocytosis of insulin granules 
(Côté et al., 2014; Gheni et al., 2014;). Incretins, 
GLP-1 and GIP, act as paracrine signaling 
molecules by interacting with G-protein coupled 
receptors (GPCRs) to accelerate insulin secretion 
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 in a glucose-dependent manner via cyclic AMP 
(cAMP) signaling; however, this phenomenon is 
not presented in Figure 2. Proposed by multiple 
sources, a possible mechanism for the amplifying 
effects of incretins on insulin secretion links 
glutamate, a product of the malate-aspartate 
(MA) shuttle, as the key factor for combination 
(Côté et al., 2014; Gheni et al., 2014). Upon 
stimulation of a specific G protein in the 
membrane of a pancreatic  cell via an incretin 
molecule, cAMP/protein kinase A signaling 
allows insulin granules to uptake glutamate 
produced from the malate-aspartate shuttle, 
thereby increasing the secretion of insulin. 
1.d. Satiety Hormone Secretion via T1R2/T1R3 
Receptor: NNS Glucose Structural Analogy and 
Macronutrient Pairing 
 
Nonnutritive sweeteners have been predicted to 
elicit a response, similar to glucose, which 
potentiates levels of GLP-1; however, many 
studies dealing specifically with human subjects 
saw no response to predicted incretin levels, 
indicating a deficiency in the release of incretins 
via enteroendocrine cells. Incretins’ ability to 
potentiate insulin secretion, promote satiety, and 
prolong gastric emptying make them a critical 
component to glucose regulation and 
Figure 2. GLP-1 Secretion via T1R2/T1R3 Receptor. The intracellular mechanism outlined in the above figure 
provides a possible relationship between the intracellular cascade observed in type II taste cells and enteroendocrine 
cells in the gut. The mechanism in the taste buds is as follows: T1R2/T1R3 receptor stimulation; dissociation of the 
heterotrimeric guanine-nucleotide-binding G protein and , , and  subunits (-gustducin, G3, and G13); increase 
in phospholipase C-2 (PLC-2); inositol 1,4,5-triphosphate (IP3) receptor releases Ca2+ from intracellular stores; 
opening of transient receptor potential cation channel subfamily M member 5 (TRPM5); membrane depolarized; action 
potential built; release of ATP. Enteroendocrine cells are predicted to follow a similar pathway via stimulation of the 
T1R2/T1R3 receptor where the action potential from Ca2+ built up acts as the driving force for the secretion of incretins, 
gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1(GLP-1). Upon stimulation of the T1R2/T1R3 receptor 
via sweet-tasting molecule, incretins are released, and the expression of sodium-glucose transporter-2 (GLUT-2) 
increases. This figure (Lafitte et al., 2014) has been reproduced with permission from Wolters Kluwer Health, Inc.  
 
 
 
figure 
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 consumption patterns. Several studies, 
summarized in Table 1, assessed the implications 
of various NNS (sucralose, acesulfame 
potassium, aspartame, and Rebaudioside A) and 
polyol sweeteners (erythritol and exylitol) on 
GLP-1 secretion. 
 
While focusing on studies dealing with human 
subjects, the experiments done in vivo were 
discordant in their findings. Wölnerhanssen et al. 
(2016) found that xylitol and erythritol, polyol 
sweeteners, caused a significant increase in GLP-
1 levels in both lean (5) and obese (5) subjects 
compared to a control, an intragastric infusion of 
just water. Methods that delivered treatments via 
intragastric infusion involved a catheter tube that 
allowed for direct administration to the 
duodenum, bypassing the digestive processes that 
occur prior. Additionally, administering a 
“glucose load” consisted of consuming 75 g of 
glucose after NNS exposure. Polyols are not 
technically nonnutritive because they are 
partially metabolized, but over 90% of erythritol 
is absorbed then excreted by the kidney, and 
xylitol is readily fermented by bacteria in the gut. 
Hence, their actual caloric intake is much lower 
than that of glucose. With no prior intake or 
glucose administration, insulin levels remained 
low, indicating the glucose-dependent nature of 
insulin secretion. It is worthy to note that this 
study used extremely high amounts of sweetener 
in their infusions (50g of xylitol and 75g of 
erythritol), which are unrealistic to typical 
consumption amounts as these usually appear in 
lower concentrations. The structural similarity 
between polyols and glucose was a proposed 
cause for the increased levels of GLP-1. Two 
other studies that followed a similar intragastric 
infusion method in human subjects; Ma et al. 
(2009) and Steinert et al. (2011) observed no 
difference in GLP-1 levels upon sucralose, 
aspartame, and acesulfame potassium 
administration. Steinert et al., suggested that the 
secretion of GLP-1 depended more than just the 
detection sweetness or that it was reliant on a 
structural analogy to glucose. Rather than using 
infusions, many in vivo studies assessed NNS 
impact on GLP-1 by method of a dissolved drink, 
either commercial diet sodas or custom 
concoctions. This method more accurately 
represents the physiological conditions in which 
NNS would exist as the quantities of 
administered NNS were lower and the digestive 
path incorporated all components of the 
gastrointestinal tract. In doing this, they all also 
administered a 75g oral glucose tolerance test 
(OGTT) 10-15min after exposure to NNS to test 
responses to GLP-1, insulin, and blood glucose 
levels. Temizkan et al. (2015) administered 
sucralose to normal and diagnosed type 2 diabetic 
Table 1. Summarized Results of NNS Impact on GLP-1 Secretion. 
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 subjects and found that it enhanced GLP-1 levels 
in only healthy subjects. Additionally, they saw 
lower levels of blood glucose in the normal 
patients after NNS introduction compared to the 
control (water). This study highlights the 
metabolic deficiencies in diabetic patients and 
proposes NNS as possible targets for prevention 
of this onset disease. Brown et al. (2009) saw a 
greater increase in GLP-1 levels after drinking 
240mL diet soda (sweetened with sucralose and 
Ace K) compared to the control (carbonated 
water). They concluded that NNS has an 
enhancing effect on the GLP-1 release by 
synergizing with glucose. With aims to clarify the 
real impact of NNS on GLP-1 release, a study 
conducted by Wu et al., conducted similar 
conditions; however, instead of using a 
commercial diet soda, they used pure sucralose 
and Ace K dissolved in water with no added 
substances found in the diet soda used by Brown 
et al. (caramel color, gum acacia, natural flavors, 
citric acid, potassium benzoate, phosphoric acid, 
and potassium citrate). Their results yielded no 
difference in GLP-1 secretion when exposed to 
NNS versus the control (water). These two 
studies, Brown et al. and Wu et al. (2009), present 
the possibility that the added components found 
in the diet soda that Brown et al. used could have 
contributed, in combination with NNS, to the 
enhancing effect of GLP-1 more so than the NNS 
alone. 
 
Approximately half of the in vivo studies 
observed an increase in GLP-1 levels, whereas 
the other half saw no increase. The majority of the 
results are not in complete agreement; however, 
there is moderate evidence suggesting that NNS 
can an impact GLP-1 secretion within in vivo 
experimentation. The experiments conducted in 
controlled cell lines (in vitro) were more 
congruent in their findings. Geraedts et al. (2012) 
took eight healthy human mucosal tissue samples 
from the duodenum via gastroduodenoscopy and 
found that sucralose and Ace K alone could 
induce GLP-1 secretion, but their effects were 
enhanced when pea protein was added in 
combination to the cell lines. In agreement with 
Brown et al., they deduced that NNS sucralose 
and Ace K may synergize with a macronutrient to 
enhance satiety hormone secretion. Jang et al. 
demonstrated a positive correlation between NNS 
sucralose and GLP-1 secretion in post mortem 
human duodenum cell lines. When lactisole, a 
known sweet receptor inhibitor was introduced, 
the secretion of GLP-1 was diminished, 
supporting the hypothesis that involves the 
T1R2/T1R3 sweet taste receptor and incretin 
release. In derived mouse cell lines, van der 
Wielen et al. (2016) also observed a clear increase 
in GLP-1 secretion (4.3 fold in the ileum) when 
directly exposed to Rebaudioside A. More so than 
the in vivo experiments, the in vitro studies 
provide evidence for a direct correlation between 
the stimulation of the T1R2/T1R3 receptor and 
GLP-1 secretion. Remarkably, they proved that 
NNS can induce this pathway; however, in vitro 
experiments are restricting in their results due to 
the controlled setting and limiting factors. 
 
NNS DISRUPT THE GUT MICROBIOTA 
COMPOSITION 
 
2.a. The Importance of the Gut Microbiota on 
Metabolism 
 
The human gut microbiota, consisting of mostly 
bacteria (>90%), archaea, viruses, and unicellular 
organisms, is linked to physiological and 
digestive capacities that humans have yet to 
evolve independently. Specific to the intestinal 
tract, the gut microbiota aids in detoxification, 
vitamin synthesis, immunity, and digestion by 
secreting enzymes for substances otherwise non-
digestible (D’Argenio et al., 2015). Alterations in 
the gut microbiome have been linked to abnormal 
metabolic deficiencies as well as obesity, 
diabetes, and chronic inflammation (Philippaert 
et al., 2017). These alterations can be stimulated 
by internal and external factors including diet, 
age, hormonal cycles, therapies, and illness. It is 
important to note that the composition of 
microflora within host species develops from 
distinct selective pressures and inherited genetic 
factors; therefore, the composition will differ 
significantly from person to person and even 
more so from humans to other mammals (mice, 
swine, and rats) (Daly et al., 2014). Disruptions 
in the gut microbiota are widely recognized as an 
operative contributor that lead to the development 
of obesity and insulin resistance (Nettleton et al., 
2016).  Consisting of 400-1000 adherent and non-
adherent bacterial species, the majority of the 
bacteria in the microbiome (>90%) belong to one 
8
DePaul Discoveries, Vol. 7 [2018], Iss. 1, Art. 5
https://via.library.depaul.edu/depaul-disc/vol7/iss1/5
 of the two major phyla, the Firmicutes and the 
Bacteroidetes (Nettleton et al., 2016; Philippaert 
et al., 2017). A convincing, but not definite, 
characteristic of obesity and type II diabetes is 
associated with a high ratio of Firmicutes to 
Bacteroidetes (Drasar et al., 1972; Nettleton et 
al., 2016; Palmnäs et al., 2014). The ratio between 
them is thought to influence metabolic processes 
and susceptibility to onset metabolic syndrome 
(Nettleton et al., 2016), but due to the specificity 
and variability of microbiomes, this ratio has 
been questionable as plenty of healthy patients 
showed high ratios of Firmicutes to Bacteroidetes 
and vice versa (Frankenfeld et al., 2015). In 
accordance with these recent findings, the impact 
of NNS on the gut microbiota has gained serious 
attention. 
  
2.b. NNS-Induced Disruptions in the Gut 
Microbiota via Membrane-Spanning Receptors 
and Production of SCFA 
 
Literature research on NNS and the gut 
microbiota yielded very few studies that failed to 
disprove their null hypothesis, but the majority of 
the experiments conducted were carried out with 
non-human mammals as their subjects. The core 
studies are summarized in Table 2 and are 
referenced throughout the text, ranging from 
results that showed NNS to be harmful (impaired 
metabolic responses), beneficial, or non-affecting 
to the function of metabolic responses. 
Additionally, a supplementary figure, detailing 
the taxonomic classification of bacteria involved 
in the following studies, was developed to display 
the relationship between bacterial species and 
their predicted metabolic impacts (see Figure 3). 
 
Palmnäs et al. (2014) assessed the effect of low-
dose aspartame on the microbiome composition 
and glycemic responses on male Sprague-Dawley 
rats. They found that aspartame-consuming rats 
consumed fewer calories and gained less weight 
than the control diet (water); however, the 
aspartame group displayed elevated fasting 
glucose levels and impaired insulin-stimulated 
glucose disposal. Analysis of their microbiome 
composition revealed an increase in the 
Firmicutes to Bacteroidetes ratio, specifically, 
overall increases in the abundance of 
Enterobacteriaceae, Roseburia, and Clostridium 
leptum. In addition, they observed increased 
amounts of the short chain fatty acid (SCFA) 
propionate, a highly gluconeogenic substrate, in 
the aspartame-consuming group. The rising 
abundance of SCFA propionate was most likely a 
result of the increase in Clostridium spp. as it 
produces this metabolite during fermentation 
(Puertollano et al., 2014). This study shows the 
possibility of NNS interacting with bacteria in the 
gut to induce production of a bacterial end 
product, SCFA propionate, which is known to 
impair insulin function and elevate glucose levels 
(Palmnäs et al., 2014; Ximenes et al., 2007). Suez 
et al. also observed a NNS-induced glucose 
intolerance and attributed it to alterations in the 
gut microbiota. Exposure to NNS saccharin in 
mice lead to increasing levels of 
Enterobacteriaceae, Bacteroides, and some 
Table 2. Summarized Results of NNS Impact on the Gut Microbiota. 
 
NGS = Next-Generation Sequencing.                                        
qPCR = Quantitative polymerase  chain reaction assay 
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 Clostridiales, and decreasing amounts of 
Lactobacilli spp. and other Clostridiales. These 
bacterial compositional characteristics were 
accompanied by increased glycemic responses. 
After introducing antibiotic A (ciprofloxacin and 
metronidazole) and antibiotic B (vancomycin), 
the glycemic responses returned to normal levels 
that were comparable to the control group 
(water), suggesting that the changes in bacteria 
abundance were directly responsible for the 
impaired glycemic response. Failing to do an 
analysis of the microbiome post-antibiotic 
treatment, this study did not determine what 
differentiated between the two microbiome 
compositions. In an additional phase, they 
introduced saccharin treated bacterial colonies 
from affected mice and 7 humans to germ-free 
mice and saw similar trends in their rising blood 
glucose levels, verifying the importance of the 
gut microbiota composition on glucose 
homeostasis.  Possible mechanisms for the 
alterations in bacteria and the resulting glycemic 
responses were not identified in this study. 
Frankenfeld et al. (2015), one of the few studies 
dealing with human subjects, assessed fecal 
bacterial composition upon exposure to 
aspartame and Ace K. They found no significant 
alterations in composition makeup (See Table 2). 
    
In contrast to the previous studies, Daly et al. 
(2014) demonstrated a scenario in which 
commercial NNS SUCRAM™ (saccharin/ 
NHDC) was beneficial to swine hosts by 
increasing the amounts of anti-inflammatory and 
immune-protecting Lactobacillus. Consisting of 
two experimental groups (standard wheat diet 
plus lactose or SUCRAM™) and a control group 
(standard wheat diet), they found a significant 
enhancement of caecal Lactobacillus populations 
in the lactose and SUCRAM™-exposed swine 
groups. Lactobacillus grow anaerobically by 
fermenting sugars to produce lactic acid, a 
metabolic product that was found in noticeably 
larger quantities in their experimental groups. In 
order to maximize their fermentation capacities, 
Lactobacillus have evolved multiple sugar 
transport and metabolic systems, which are 
initiated at their receptors by substrates (Daly et 
al., 2014). In the conclusion of their study, they 
proposed that certain members of the genus 
Lactobacillus have specific membrane-spanning 
receptor proteins that interact with one or both of 
the components of SUCRAM™, saccharin and/or 
neohesperidin dihydrochalcone (NHDC), to 
induce rapid growth in a similar way that lactose 
would. In a follow up study, Daly et al. narrowed 
the exact Lactobacilli species (Lactobacillus 
4228) responsible for the highest rates of growth 
and determined the cause of the proliferation to 
be a result of a reduced lag-phase in cell division 
(Daly et al., 2016). In vitro analysis revealed that 
NHDC (one component of SUCRAM™) was 
Figure 3. Taxonomic Classification of Notable Bacteria Impacted by NNS. Groups outlined in green are 
predicted to have a positive impact on metabolic and glycemic responses when abundance is increased. In 
contrast, those outlined in red are predicted to have negative impacts on metabolic processes when abundance is 
increased. An increased ratio of phyla Firmicutes : Bacteroidetes is associated with various metabolic 
deficiencies, such as type II diabetes and obesity, and can be visualized in the figure. 
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 held most responsible for the accelerated growth 
patterns, confirming NHDC as the substrate for a 
specific membrane-spanning receptor protein. 
NNS NHDC is not approved for use in the United 
States; however, it is generally recognized as safe 
by the FDA. 
  
CONCLUSIONS 
 
NNS have established a strong presence in the 
common diet and continue to surround us in areas 
beyond perceived ingestion such as personal care 
products like toothpaste (Sylvetsky et al., 2017). 
As they are regularly recommended to 
individuals either prone to or experiencing 
metabolic deficiencies due to their non-caloric 
reputation, their impact post-consumption should 
be further examined due to the overwhelming 
evidence that supports the notion that NNS are 
likely metabolically active. While comparing 
studies that used different NNS and 
concentrations, species of subjects, and 
administrative processes (i.e. in vitro vs. in vivo), 
it is essential to consider their experimental 
differences as a contributor to their disagreement 
in results. The evidence surrounding the NNS-
induced secretion of GLP-1 are consistent in most 
in vitro studies conducted with both human and 
other mammalian cell lines, supporting the 
hypothesis that NNS (sucralose & Ace K) interact 
with the T1R2/T1R3 taste receptor to aid in GLP-
1 secretion (Geraedts et al., 2012; Jang et al., 
2007; van der Wielen et al., 2016). Additionally, 
xylitol and erytrhitol, two sweeteners that are not 
technically nonnutritive, potentiated GLP-1 
levels at high concentrations in vivo possibly due 
to their structural similarity to glucose 
(Wolnerhanssen et al., 2016). Contrary to this, the 
majority of studies done in vivo on humans 
determined that NNS (sucralose and Ace K) 
could not potentiate GLP-1 secretion 
independently (Ma et al., 2009; Steinert et al., 
2011; Temizkan et al., 2015; Wu et al., 2013), and 
those that saw increased GLP-1 levels deduced 
that a synergistic effect between NNS and a 
macronutrient caused the enhanced incretin 
secretion (Brown et al., 2009). This intensified 
release of GLP-1 via NNS and macronutrients in 
combination was supported in Geraedts et al. 
where they observed significantly higher 
amounts of GLP-1 secretion when pea protein 
was added to cell lines affected by sucralose and 
Ace K (Geraedts et al., 2012). As NNS are 
commonly consumed in combination with a meal 
in hopes of reducing sugar content, the pairing of 
NNS and macronutrient will likely induce 
secretion of GLP-1 and elicit an uptake response 
similar to that of glucose. In contrast, an inability 
for NNS to trigger post-ingestive responses, such 
as the secretion of GLP-1, can influence 
downstream digestion in a negative manner 
where conditioned response would be disrupted 
and secretion levels of insulin would be reduced; 
therefore, further experimentation is necessary to 
determine their definite effect on the secretion of 
satiety hormone, GLP-1. 
  
Dysbiosis in the human gut microbiota is now 
considered a legitimate cause and characteristic 
of people either approaching or exemplifying 
obesity (David et al., 2014; Turnbaugh et al., 
2006). The majority of studies assessing the 
effect of NNS on the gut microbiome 
composition observed some degree of dysbiosis. 
One damaging result of the dysbiosis after 
aspartame consumption in rats, observed by 
Palmnäs et al. (2014), increased the production of 
SCFA propionate, a gluconeogenic substrate, via 
Clostridium spp. Propionate impairs insulin 
function and elevates glucose levels, creating a 
detrimental environment for someone attempting 
to avoid obesity and type 2 diabetes. In converse, 
Daly et al. (2016) observed a positive form of 
dysbiosis by the increase in beneficial 
Lactobacillus spp. in saccharin and NHDC 
induced swine. The specific cause of increase in 
Lactobacilli population was attributed to a 
reduced lag-phase induced by NHDC, a NNS 
component of commercial SUCRAM™. 
  
Altogether, the evidence presented in this review 
highlights the conflicting results regarding NNS 
and their integration into diet; NNS and their 
impact on hormone secretion and the gut 
microbiome require additional research to 
succinctly link their relationships. In combatting 
obesity and diabetes, these two non-mutually 
exclusive components of our metabolism serve as 
excellent target points for treatments and 
prevention. GLP-1 agonists are currently 
implemented as a new treatment method for type 
2 diabetes due to their insulin-enhancing and 
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 satiety characteristics, and probiotic/antibiotic 
treatments on patients have shown potential to 
change human bacterial composition in ways that 
are beneficial for regulating intestinal 
permeability, inflammation, and glycemic 
responses (Cani et al., 2008; Yadav et al., 2013). 
Further investigations, specific to human 
subjects, should be explored in order to assess the 
true extent to which NNS impact incretin 
secretion and alteration in the gut microbiota as 
well as the inter-communication between these 
two components.  
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